HealthcareSARS-CoV-2 antigen levels linked to patient outcomes

SARS-CoV-2 antigen levels linked to patient outcomes


SARS-CoV-2
Transmission electron micrograph of SARS-CoV-2 virus particles (colored yellow) within the endosomes of a heavily infected nasal olfactory epithelial cell. Credit: NIAID

The amount of SARS-CoV-2 antigen measured in the blood of patients hospitalized with COVID-19 is associated with illness severity and other clinical outcomes, according to a new study published in the Annals of Internal Medicine. Following the ACTIV-3 trial of COVID-19 therapeutics in people hospitalized with COVID-19, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and their collaborators analyzed levels of SARS-COV-2 antigen in blood samples taken from study participants and assessed the association of those levels with disease progression. Higher levels of viral antigen in the blood, which could indicate ongoing SARS-CoV-2 replication, correlated with more severe disease. The authors suggest that SARS-CoV-2 antigen levels hold promise as a biomarker, or a measurable substance, to predict which patients hospitalized with COVID-19 have a higher risk of worse outcomes.

The ACTIV-3 trial enrolled people hospitalized with COVID-19 between August 2020 and November 2021. Participants contributed a baseline and were then randomized to receive either an experimental COVID-19 therapeutic or a placebo. All participants received the antiviral remdesivir unless contraindicated. In this follow-up analysis, the researchers examined 2540 participant baseline for SARS-CoV-2 antigen levels.

The researchers assessed the relationship between each participantโ€™s SARS-CoV-2 blood antigen levels and their time to discharge from the hospital, as well as their pulmonary symptoms at Day 5 of the trialโ€”whether they had stayed the same, worsened, or improved since enrollment. With all this information in hand, the researchers conducted statistical analyses to determine if plasma antigen levels were associated with the participantsโ€™ pulmonary function when they gave the blood sampleโ€”and whether they could predict how the participants would fare over time. In addition, the researchers examined the relationship between a number of participant and viral characteristics and antigen levels.

The analysis revealed a strong correlation between higher SARS-CoV-2 antigen levels (โ‰ฅ1000 nanograms per liter) and worse pulmonary function at the time of enrollment. Importantly, participants with higher SARS-CoV-2 antigen levels in the blood at enrollment generally had decreased pulmonary function at Day 5, regardless of the severity of their illness at the time of study entry, and took longer to be released from the hospital. High blood antigen levels also correlated with some known risk factors for worse illness, such as being male. Three additional participant characteristics were found to correlate with lower antigen levels: the presence of SARS-CoV-2 antibodies, exposure to remdesivir prior to enrollment and longer time in hospital prior to enrollment. Finally, participants infected with the delta variant had higher antigen levels than those infected with prior circulating strains. The researchers concluded that antigen levels in the are likely a marker of ongoing viral replication and could be useful for predicting a patientโ€™s and likely outcomes once they are admitted to the hospital. The authors note that these results suggest that a precision medicine approach could be helpful in future clinical trials of antiviral therapy. For instance, antigen levels could help determine those patients most likely to benefit from therapies directed at fighting the virus.


Efficacy of bamlanivimab for COVID-19 may vary with antibody status


More information:
The association of baseline plasma SARS-CoV-2 nucleocapsid antigen level and outcomes in patients hospitalized with COVID-19, Annals of Internal Medicine (2022). DOI: 10.7326/M22-0924

Citation:
SARS-CoV-2 antigen levels linked to patient outcomes (2022, August 29)
retrieved 29 August 2022
from https://medicalxpress.com/news/2022-08-sars-cov-antigen-linked-patient-outcomes.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Original Source Link

Latest News

How Davos leaders are responding to Trumpโ€™s DEI crackdown

Investment in diversity is unlikely to dry up because of Trumpโ€™s moves, said bankers at World Economic Forumโ€™s...

Bitcoin To $122K Next Month? Research Predicts Big Move

Este artรญculo tambiรฉn estรก disponible en espaรฑol. Many analysts are ruminating on the next significant milestone, as the remarkable...

ByteDance plans to spend $12bn on AI chips this year

This article is an on-site version of our FirstFT newsletter. Subscribers can sign up to our Asia, Europe/Africa...

Scale AI faces a lawsuit by six people who worked on its Outlier platform, claiming they were forced to write disturbing prompts about violence...

Charles Rollet / TechCrunch: Scale AI faces a lawsuit by six people who worked on its Outlier platform,...

Trump is trying to fire most of the White Houseโ€™s civil liberties watchdog

President Donald Trump is reportedly seeking to ax most of the members of an internal watchdog agency that...

Must Read

Supporting LA Wildfire Victims โ€“ Redfin

Popular homes for sale$5,959,0004 beds, 4 baths, ...

Is Carrie Underwood a Republican? What Sheโ€™s Said Over the Years โ€“ Hollywood Life

Carrie Underwood has performed at Donald Trumpโ€˜s presidential...
- Advertisement -

You might also likeRELATED
Recommended to you